Nymox Pharmaceutical (NYMX) Stock News, Jun 19, 2020

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) has successfully advanced its regulatory submission preparations, with most documentation completed despite pandemic-related challenges. CEO Dr. Paul Averback noted the team’s extraordinary effort in meeting timelines and expects to file applications by the end of Q3 or early Q4. The company remains optimistic about the future, highlighting the unmet medical need for treatments related to prostate issues. They commend their recent successes in intellectual property for Fexapotide, aimed at treating prostate enlargement and cancer.